ENXTBR:ARGXBiotechs
A Look At Argenx (ENXTBR:ARGX) Valuation After First Operating Profit And Positive Vyvgart Phase 3 Data
argenx (ENXTBR:ARGX) is back in focus after reporting its first year of annual operating profitability and sharing positive Phase 3 Vyvgart data in ocular myasthenia gravis, which is sharpening investor attention on its autoimmune portfolio.
See our latest analysis for argenx.
argenx’s latest scientific updates and its first full year of operating profitability come after a period where the share price has faced a 9.34% 1 month and 17.93% 3 month share price return decline, even as the 1 year...